Alzheimer’s disease
Conditions
Interventions
People at risk of AD (stage 0-1):The group was randomly divided into two subgroups, the RIC intervention group and the Non-RIC intervention group, according to a 1:1 ratio.
The ischemic preconditionin
Patients with early AD (stage 2-3):The group was randomly divided into two subgroups, the RIC intervention group and the Non-RIC intervention group, according to a 1:1 ratio.
The ischemic precondition
Patients with mild to moderate AD (stage 4-5):The group was randomly divided into two subgroups, the RIC intervention group and the Non-RIC intervention group, ac
Sponsors
North China University of Science and Technology
Eligibility
Sex/Gender
All
Age
45 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1) Participants aged 45-90, regardless of gender. 2) Individuals exhibiting baseline health data indicative of a high risk of Alzheimer's disease, such as those with diabetes, insomnia disorders, hypertension, sarcopenia, endocrine disorders, etc. 3) Patients diagnosed with Alzheimer's disease risk groups, early to mild cognitive impairment, or mild to moderate Alzheimer's disease, as per the consensus of Chinese experts on the diagnosis and treatment of Alzheimer's disease-induced mild cognitive impairment (MCI) in 2024 and 2023 AA clinical diagnostic criteria (draft). 4)Sign the informed consent form and be eligible to receive interventional treatment
Exclusion criteria
Exclusion criteria: 1) Individuals with erysipelas, acute inflammatory skin conditions, severe limb necrosis, or infections. 2) Patients diagnosed with malignant tumors. 3) Individuals suffering from limb venous thrombosis. 4) Individuals exhibiting uncontrolled infections or unexplained fevers. 5) Patients with a systolic blood pressure greater than or equal to 180mmHg and/or a diastolic blood pressure less than or equal to 110mmHg. 6) Those with peripheral vascular disease, including severe vascular damage due to diabetes. 7) Individuals with coagulation disorders (e.g., hemophilia, leukemia) or active internal bleeding. 8) Patients with severe or critical conditions related to heart, lung, liver, kidney, or other vital organs, which are not controlled or stable. 9)Subjects who refuse to sign the informed consent form and have poor compliance."
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MMSE;Plasma Aß42/40; | — |
Secondary
| Measure | Time frame |
|---|---|
| NPI;Plasma glial fibrillary acidic protein;Plasma neurofilament light protein; | — |
Countries
China
Contacts
Public ContactLiangdan Sun
North China University of Science and Technology
Outcome results
None listed